Observational studyScientific reports2021
Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
Observational study in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- [Clinical and immunological features for early differentiation between primary immune thrombocytopenia and connective tissue disease in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases.Arthritis research & therapy · 2025Observational
- Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study.Rheumatology advances in practice · 2024Article
- Refractory Acquired Amegakaryocytic Thrombocytopenia with Rapid Progression to Aplastic Anaemia in SLE.Mediterranean journal of rheumatology · 2023Article
- RNA modification: mechanisms and therapeutic targets.Molecular biomedicine · 2023Review
- Methyltransferase-like proteins in cancer biology and potential therapeutic targeting.Journal of hematology & oncology · 2023Review
- The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.Clinical rheumatology · 2023Review
- METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey.Journal of medicinal chemistry · 2023Review
- Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the mPharmaceuticals (Basel, Switzerland) · 2022Article
- Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?Biomedicines · 2021Review
- Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the efficacy and safety of eltrombopag in connective tissue disease (CTD)-immune thrombocytopenia (ITP), we conducted this single-center retrospective observational study, including patients with refractory CTD-ITP who were treated with eltrombopag between January 2018 and August 2019. The characteristics of patients at baseline, and the efficacy and safety of the drug were analyzed. The predictors for a response were analyzed using a univariate analysis such as Chi-square or nonparametric test and a multiple correspondence analysis (MCA) method. A total of 15 patients with refractory CTD-ITP were included in the study. Their median age at the time of inclusion was 40.6 years. The median platelet count at initiation of eltrombopag was 11.53 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.